Literature DB >> 16466849

Matrix metalloproteinase-9 polymorphisms and renal cell carcinoma in a Japanese population.

Yasuo Awakura1, Noriyuki Ito, Eijiro Nakamura, Takeshi Takahashi, Hirokazu Kotani, Yoshiki Mikami, Toshiyuki Manabe, Toshiyuki Kamoto, Tomonori Habuchi, Osamu Ogawa.   

Abstract

Matrix metalloproteinase-9 (MMP-9) plays a pivotal role in cancer invasion and metastasis. Recently, experimental study has shown that MMP-9 is also implicated in early carcinogenesis. We hypothesized that MMP-9 polymorphisms influence the predisposition to develop renal cell carcinoma (RCC). To test the hypothesis, we determined MMP-9 C-1562T and R279Q genotypes in Japanese RCC cases (n=179) and controls (n=211). Furthermore, we investigated the relationship between MMP-9 polymorphisms and clinicopathological features. The distribution of C-1562T and R279Q genotypes was not significantly associated with the risk of RCC (odds ratio [OR]=1.14, 95% confidence interval [CI]=0.73-1.77 for -1562 CT/TT genotypes versus CC genotype; OR=1.29, 95% CI=0.86-1.93 for 279 RQ/QQ genotypes versus RR genotype). However, the distribution of R279Q genotypes was significantly associated with the histological grade (P<0.01). The present results suggest that MMP9 R279Q polymorphism has influence on the malignant potential of RCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16466849     DOI: 10.1016/j.canlet.2005.10.005

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  14 in total

1.  Matrix metalloproteinase 9 gene polymorphisms are associated with a multiple family history of gastric cancer.

Authors:  Rieko Okada; Mariko Naito; Yuta Hattori; Toshio Seiki; Kenji Wakai; Hinako Nanri; Miki Watanabe; Sadao Suzuki; Tara Sefanya Kairupan; Naoyuki Takashima; Haruo Mikami; Keizo Ohnaka; Yoshiyuki Watanabe; Sakurako Katsuura-Kamano; Michiaki Kubo; Nobuyuki Hamajima; Hideo Tanaka
Journal:  Gastric Cancer       Date:  2016-04-06       Impact factor: 7.370

2.  Functional polymorphisms of matrix metalloproteinase-9 and survival in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy.

Authors:  Huai Liu; Pei-Yu Huang; Lin-Quan Tang; Qiu-Yan Chen; Ying Zhang; Lu Zhang; Ling Guo; Dong-Hua Luo; Hao-Yuan Mo; Yan-Qun Xiang; Fang Qiu; Rui Sun; Ming-Yuan Chen; Yi-Jun Hua; Xing Lv; Lin Wang; Chong Zhao; Xiang Guo; Ka-Jia Cao; Chao-Nan Qian; Ming-Huang Hong; Hai-Qiang Mai
Journal:  Med Oncol       Date:  2013-08-18       Impact factor: 3.064

3.  Update analysis of studies on the MMP-9 -1562 C>T polymorphism and cancer risk.

Authors:  Li-Feng Zhang; Yuan-Yuan Mi; Qiang Cao; Wei Wang; Chao Qin; Jun-Feng Wei; Yao-Jun Zhou; Yong-Fei Li; Min Tang; Wei-Min Liu; Wei Zhang; Jian-Gang Zou
Journal:  Mol Biol Rep       Date:  2011-06-30       Impact factor: 2.316

4.  MMP9 limits apoptosis and stimulates branching morphogenesis during kidney development.

Authors:  Catherine Arnould; Martine Lelièvre-Pégorier; Pierre Ronco; Brigitte Lelongt
Journal:  J Am Soc Nephrol       Date:  2009-08-27       Impact factor: 10.121

5.  Matrix metalloproteinase-9-1562C>T polymorphism may increase the risk of lymphatic metastasis of colorectal cancer.

Authors:  Li-Li Xing; Zhen-Ning Wang; Li Jiang; Yong Zhang; Ying-Ying Xu; Juan Li; Yang Luo; Xue Zhang
Journal:  World J Gastroenterol       Date:  2007-09-14       Impact factor: 5.742

6.  MMP1, 2, 3, 7, and 9 gene polymorphisms and urinary cancer risk: a meta-analysis.

Authors:  Liu Tao; Zuo Li; Li Lin; Yin Lei; Yu Hongyuan; Jing Hongwei; Liu Yang; Kong Chuize
Journal:  Genet Test Mol Biomarkers       Date:  2015-08-24

7.  Contemporary epidemiology of renal cell cancer.

Authors:  Wong-Ho Chow; Susan S Devesa
Journal:  Cancer J       Date:  2008 Sep-Oct       Impact factor: 3.360

8.  Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis.

Authors:  Dan Liu; Hong Guo; Yafei Li; Xueqing Xu; Kang Yang; Yun Bai
Journal:  PLoS One       Date:  2012-02-14       Impact factor: 3.240

9.  The expression and clinical significance of matrix metalloproteinase 7 and tissue inhibitor of matrix metalloproteinases 2 in clear cell renal cell carcinoma.

Authors:  Hongsheng Lu; Zhaohui Yang; Hui Zhang; Meifu Gan; Tao Zhou; Siling Wang
Journal:  Exp Ther Med       Date:  2012-12-17       Impact factor: 2.447

10.  Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma.

Authors:  Javier Cotignola; Boris Reva; Nandita Mitra; Nicole Ishill; Shaokun Chuai; Ami Patel; Shivang Shah; Gretchen Vanderbeek; Daniel Coit; Klaus Busam; Allan Halpern; Alan Houghton; Chris Sander; Marianne Berwick; Irene Orlow
Journal:  BMC Med Genet       Date:  2007-03-08       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.